A prognostic matrix code defines functional glioblastoma phenotypes and niches
Monika Vishnoi1,2, Zeynep Dereli3, Zheng Yin4
1Department of Neurosurgery, Houston Methodist Research Institute, Houston, TX, 77030 USA.
Research Square
|October 4, 2023
Summary
Glioblastoma (GBM) matrisome gene expression defines tumor subtypes linked to patient survival and immune cell infiltration. A 17-gene signature may predict responses to PD1 blockade therapy.
Area of Science:
- Oncology
- Immunology
- Genomics
Background:
- Interactions between tumor, immune, and vascular niches are critical in glioblastoma (GBM) malignancy and treatment resistance.
- The composition and role of extracellular matrix proteins (CMPs) in mediating these interactions within GBM are not fully understood.
Conclusions:
- The "matrix code" of CMPs offers insights into GBM heterogeneity and progression.
- Matrisome gene expression patterns can identify GBM subtypes with distinct clinical outcomes and immune microenvironments.
- This research provides potential biomarkers for optimizing glioblastoma treatment strategies, including immunotherapy.
More Related Videos
06:32Evaluation of Biomarkers in Glioma by Immunohistochemistry on Paraffin-Embedded 3D Glioma Neurosphere Cultures
Published on: January 9, 2019
7.9K
09:40Characterization of Functionally Associated miRNAs in Glioblastoma and their Engineering into Artificial Clusters for Gene Therapy
Published on: October 4, 2019
5.7K
